The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 28, 2021
Filed:
Sep. 10, 2018
Applicant:
Novartis Ag, Basel, CH;
Inventors:
Assignee:
Novartis AG, Basel, CH;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/46 (2006.01); A61K 9/48 (2006.01); A61P 1/16 (2006.01); A61K 9/08 (2006.01); A61K 47/14 (2017.01);
U.S. Cl.
CPC ...
A61K 31/46 (2013.01); A61K 9/08 (2013.01); A61K 9/4825 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 47/14 (2013.01); A61P 1/16 (2018.01); A61K 9/4833 (2013.01);
Abstract
The present invention relates to a pharmaceutical composition for oral administration comprising a non-bile farnesoid X receptor (FXR) agonist 2-[(1R,3R,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one lipid excipient; to a capsule for oral administration comprising said pharmaceutical composition; to the use of said pharmaceutical composition for the treatment of a FXR mediated disorder or condition; and to a process for preparing said pharmaceutical composition.